Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Achaogen
Achaogen Receives £4.1 Million Award from the Wellcome Trust to Advance Its Neoglycosides Portfolio
January 23rd, 2009
Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced that it has received a £4.1 million Seeding Drug Discovery award from the Wellcome Trust. This award will help support the investigational new drug (IND)-enabling studies and advancement into clinical trials of Achaogen’s portfolio of proprietary neoglycosides for the treatment of Gram-negative bacterial infections. Neoglycosides are Achaogen’s unique, next-generation aminoglycosides, in development to address the growing issue of multi-drug resistance to antibiotic agents....
Source: Health Business Week (2009-01-23)
|
|
Advertisement |
|
|
|
